Barclays Pounds the Table on Eli Lilly Stock (LLY) as Share Price Falls

FomoAnxiety · 2026-03-24T18:21:19+00:00

Barclays reiterates a Buy rating on Eli Lilly (LLY), targeting $1,350, as shares decline nearly 20%. Analyst Emily Field anticipates a stock rebound ahead of the new weight-loss pill approval and highlights long-term demand for obesity treatments.

FomoAnxiety

2026-03-24 18:21:19

Abstract generation in progress

British bank Barclays (BCS) continues to urge investors to buy Eli Lilly (LLY) stock as the share price falls.

Claim 30% Off TipRanks Premium

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
Stay ahead of the market with the latest news and analysis and maximize your portfolio’s potential

Analyst Emily Field reiterated a Buy rating and $1,350 price target on LLY stock on March 24. With Eli Lilly’s stock down nearly 20% on the year and trading close to $900, the shares are becoming literally too cheap to ignore, says Field.

Buying the dip in LLY stock now before the company is likely to get U.S. regulatory approval for its new weight-loss pill on April 10 would also be a smart move, according to the analyst. The weight-loss pill called Orforglipron is widely expected to be a global blockbuster and drive the company’s revenues higher.

Barclays View of LLY Stock

It was only a month ago that Barclays initiated coverage of LLY stock with a Buy-equivalent rating and the $1,350 price target. At that time, Barclays said that GLP-1 weight loss treatments represent a “durable structural shift” for the healthcare sector.

Barclays also said that it has growing confidence in long-term demand for weight-loss therapies. Field said that Eli Lilly is well-positioned to remain the global market leader in obesity treatments, and believes that LLY stock deserves a premium valuation given its strong position in the fast-growing category.

As such, Barclays named Eli Lilly its “top pharma stock to buy now.”

Is LLY Stock a Buy?

The stock of Eli Lilly has a consensus Strong Buy rating among 19 Wall Street analysts. That rating is based on 16 Buy, two Hold, and one Sell recommendations issued in the last three months. The average LLY price target of $1,247.38 implies 31.53% upside from current levels.

Disclaimer & DisclosureReport an Issue

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.